Mitochondria as a therapeutic target in heart failure.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 23219298.
- Also identified by DOI 10.1016/j.jacc.2012.08.1021 and PMC identifier 3594689.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Heart failure is a pressing public health problem with no curative treatment currently available. The existing therapies provide symptomatic relief, but are unable to reverse molecular changes that occur in cardiomyocytes. The mechanisms of heart failure are complex and multiple, but mitochondrial dysfunction appears to be a critical factor in the development of this disease. Thus, it is important to focus research efforts on targeting mitochondrial dysfunction in the failing heart to revive the myocardium and its contractile function. This review highlights the 3 promising areas for the development of heart failure therapies, including mitochondrial biogenesis, mitochondrial oxidative stress, and mitochondrial iron handling. Moreover, the translational potential of compounds targeting these pathways is discussed.
Medical subject headings
- Cardiotonic Agents
- Drug Design
- Heart Failure
- Mitochondria, Heart
- Molecular Targeted Therapy